Prostate Cancer (Prevention & Support) Protocol

OncologyModerate Evidence

supplements

Primary

Supporting

Grade A

Studies

Primary Stack

Core supplements with strongest evidence

LycopeneB

15-30mg daily

Carotenoid that accumulates in prostate tissue; inhibits androgen receptor signaling and cell proliferation

↓Cancer Markers

18 studies4,500 participants

Supporting Studies (1)

PMID: 25506817 - Lycopene and prostate cancer meta-analysis (2015)

Green Tea Extract (EGCG)B

400-800mg EGCG daily

Polyphenols inhibit PSA and androgen receptor activity; promote apoptosis in prostate cells

12 studies850 participants

Supporting Studies (1)

PMID: 19015215 - Green tea catechins and prostate cancer prevention (2009)

Supporting Stack

Additional supplements for enhanced results

Pomegranate ExtractB

500-1000mg daily (or 8oz juice)

Punicalagins inhibit prostate cancer cell growth and extend PSA doubling time

6 studies180 participants

Supporting Studies (1)

PMID: 23843106 - Pomegranate extract in prostate cancer (2013)

Vitamin D3C

2000-4000 IU daily

VDR activation promotes differentiation and inhibits proliferation in prostate cells

Cancer Mortality↓Prostate Cancer Risk

8 studies420 participants

SeleniumC

200mcg daily (selenomethionine)

Selenoproteins have antioxidant effects; supports DNA repair mechanisms

10 studies1,800 participants

Modified Citrus PectinC

15g daily

Blocks galectin-3, potentially inhibiting metastasis and tumor cell aggregation

3 studies60 participants

How This Protocol Works

Simple Explanation

Prostate cancer is influenced by androgens, oxidative stress, and inflammation. These supplements target multiple pathways involved in prostate cancer prevention and progression.

•Lycopene (from tomatoes) concentrates in prostate tissue and has been consistently associated with reduced prostate cancer risk. Meta-analyses show a 10-20% risk reduction with higher intake.

•Green tea EGCG inhibits prostate cancer cell growth and can slow PSA rise in men with existing cancer. One study showed 90% risk reduction in high-risk men taking green tea catechins.

•Pomegranate has shown promise in extending PSA doubling time—the time it takes for PSA to double, a marker of cancer progression—by 2-4 times in some studies.

•Vitamin D deficiency is associated with more aggressive prostate cancer. The vitamin D receptor is expressed in prostate tissue and regulates cell growth.

•Selenium supports antioxidant selenoproteins, though the SELECT trial showed no benefit (possibly due to population already selenium-sufficient).

Important: These supplements are supportive, not replacements for standard medical treatment. Always work with your oncologist.

Expected timeline: PSA stabilization may be seen over 6-12 months. Prevention benefits require long-term use.

Clinical Perspective

Prostate cancer pathogenesis involves androgen receptor (AR) signaling, oxidative stress, chronic inflammation, and IGF-1/PI3K/Akt pathway activation. This protocol targets these mechanisms.

•Lycopene (B-grade): Carotenoid with high prostate bioavailability. Mechanisms: AR signaling inhibition, IGF-1 reduction, antioxidant effects, connexin upregulation. Meta-analysis: pooled RR 0.81 for highest vs lowest intake (PMID: 25506817).

•EGCG (B-grade): Inhibits AR nuclear translocation, 5α-reductase type 1, and matrix metalloproteinases. Promotes apoptosis via caspase activation. RCT: 600mg/day reduced prostate cancer incidence 90% in men with HGPIN (PMID: 19015215).

•Pomegranate (B-grade): Ellagitannins metabolized to urolithins with anti-AR activity. Phase II trial: median PSA doubling time increased from 15 to 54 months (PMID: 23843106).

•Vitamin D3 (C-grade): VDR activation induces p21/p27 cell cycle arrest, promotes E-cadherin expression, inhibits Wnt/β-catenin signaling. Epidemiology: low 25-OH-D associated with aggressive disease.

•Selenium (C-grade): SELECT trial negative, but may benefit those with low baseline selenium (<122 ng/mL). Selenoproteins (GPx, TrxR) provide antioxidant defense.

•Modified citrus pectin (C-grade): Galectin-3 antagonist. Galectin-3 facilitates tumor cell adhesion and angiogenesis. Early clinical data shows PSA stabilization.

Biomarkers: PSA, PSA velocity, PSA doubling time, vitamin D level, prostate MRI.

Note: Discuss with oncology team. High-dose antioxidants may interfere with some treatments.

View All Protocols